Application of CPZ immunohistochemical antibody in differentiating hepatocellular carcinoma from other hepatoid differentiated tumors or germ cell-derived tumors

By using a combined detection strategy of CPZ protein and HepPar-1 and SALL4 markers, the problem of distinguishing hepatocellular carcinoma from hepatoid differentiated tumors in existing technologies has been solved, achieving efficient and specific tumor diagnosis, reducing the misdiagnosis rate, and supporting personalized treatment.

CN123112401APending Publication Date: 2026-11-17ZHONGSHAN HOSPITAL FUDAN UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202611246823.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-17
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing biomarkers have a high false positive rate and insufficient specificity in differentiating hepatocellular carcinoma from hepatoid differentiation or germ cell-derived tumors, leading to a high rate of misdiagnosis, especially when lesions are present in both the liver and stomach, making accurate diagnosis difficult.

Method used

Using CPZ protein as a specific biomarker, the expression of CPZ protein in biopsy or surgically resected tissue samples was detected by immunohistochemistry. Combined with HepPar-1 and SALL4 biomarkers, a dual differential diagnostic strategy was constructed. Negative CPZ results were used to exclude hepatocellular carcinoma, and the combined detection improved the accuracy of differentiation.

Benefits of technology

It enables efficient and specific differentiation between hepatocellular carcinoma and hepatoid adenocarcinoma, yolk sac tumors, and other hepatoid differentiated tumors, reducing the misdiagnosis rate and providing support for precise individualized treatment strategies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123112401A_ABST
    Figure CN123112401A_ABST
Patent Text Reader

Abstract

This invention relates to the application of CPZ immunohistochemical antibodies in differentiating hepatocellular carcinoma from other hepatoid differentiated tumors or germ cell-derived tumors, belonging to the field of biomedical detection technology. This invention provides a biomarker for differentiating hepatocellular carcinoma from other hepatoid differentiated or germ cell-derived tumors, wherein the biomarker is CPZ protein. This invention also provides the application of an anti-CPZ protein antibody in the preparation of a detection reagent for differentiating hepatocellular carcinoma from other hepatoid differentiated or germ cell-derived tumors. The differential diagnosis is achieved by immunohistochemical detection of CPZ protein expression in biopsy or surgically resected tissue samples. Other hepatoid differentiated or germ cell-derived tumors include gastric hepatoid adenocarcinoma, rectal hepatoid adenocarcinoma, gallbladder hepatoid adenocarcinoma, and yolk sac tumor. By differentiating hepatocellular carcinoma from other hepatoid differentiated or germ cell-derived tumors, support is provided for developing more precise and effective individualized treatment strategies.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the application of CPZ immunohistochemical antibody in differentiating hepatocellular carcinoma from other hepatoid differentiated tumors or germ cell-derived tumors, and belongs to the field of biomedical detection technology. Background Technology

[0002] Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver worldwide and the third leading cause of cancer-related death. In clinical pathology practice, many extrahepatic tumors can present morphological features extremely similar to HCC, such as gastric hepatoid adenocarcinoma and yolk sac tumor. Histologically, these tumors show hepatocellular differentiation, abundant eosinophilic cytoplasm, and are arranged in trabecular or nest-like patterns, highly overlapping with the morphological characteristics of HCC. Hepatoid adenocarcinoma can occur in multiple organs, including the stomach (83.9%), gallbladder, colorectal region, ovary, lung, pancreas, uterus, and bladder. It is clinically highly aggressive, often diagnosed at an advanced stage, with a poor prognosis, and is prone to liver metastasis. Simultaneously, HCC can also metastasize to the stomach. Therefore, when lesions appear in both the liver and stomach, it presents a significant challenge to pathologists in accurate diagnosis, especially in determining whether a liver lesion is primary HCC or a metastatic tumor. Misdiagnosis can directly lead to incorrect treatment decisions.

[0003] Currently, commonly used biomarkers in clinical pathological diagnosis mainly include HepPar-1, GPC3, AFP, and SALL4. However, the specificity of these biomarkers in differentiating hepatocellular carcinoma from certain hepatoid differentiated tumors is not ideal. Numerous studies have shown that GPC3 and AFP are often positively expressed in gastric hepatoid adenocarcinoma, and highly expressed in yolk sac tumors, while some yolk sac tumors can also express HepPar-1. Elevated serum AFP can be detected in 70%-80% of hepatoid adenocarcinomas, but it is also seen in hepatocellular carcinoma, yolk sac tumors, and benign liver diseases. Yolk sac tumors are a type of germ cell tumor, commonly found in the gonads, but can also occur in the mediastinum, retroperitoneum, and other sites. When yolk sac tumors metastasize to the liver, their morphology is highly similar to hepatocellular carcinoma, and immunohistochemistry often shows strong positivity for AFP and GPC3, making them easily misdiagnosed as hepatocellular carcinoma. This means that relying solely on GPC3 or AFP positivity to determine the hepatocellular origin of tumors can easily lead to misdiagnosis of extrahepatic tumors such as gastric hepatoid adenocarcinoma or yolk sac tumor as hepatocellular carcinoma. Therefore, there is an urgent clinical need for a novel biomarker that can highly specifically distinguish true hepatocellular differentiation from other hepatoid morphological imitators.

[0004] CPZ (Carboxypeptidase Z) is a secreted zinc metalloproteinase. Our team previously conducted systematic screening and validation using a large-scale clinical pathological cohort, discovering that CPZ possesses exceptionally high hepatocyte lineage specificity: 100% positive expression in normal hepatocytes; a single CPZ detection showed a sensitivity of 90.8% (any intensity of positivity) and a specificity of 81.2% for hepatocellular carcinoma, reaching 98.6% under diffuse strong positivity; in poorly differentiated hepatocellular carcinoma, the sensitivity was 91.3%, significantly superior to Arg-1 (78.26%) and HepPar-1 (82.61%). Normal hepatic bile duct tissue and intrahepatic cholangiocarcinoma tissue were almost entirely negative. This expression profile demonstrates significantly superior subtype differentiation efficacy compared to commonly used clinical hepatocyte markers such as GPC3 and HepPar-1. The findings were published in the top journal in the field of surgical pathology, the American Journal of Surgical Pathology, and are original results published by our research group (PMCID: PMC12165467). They have also been granted a national invention patent (patent number ZL202411224613.3).

[0005] In subsequent studies, we discovered an unexpected phenomenon: in various extrahepatic tumors, such as hepatocellular carcinoma and yolk sac tumors, which are easily confused with hepatocellular carcinoma morphologically, CPZ protein is almost not expressed or shows very weak focal expression. This unique expression profile makes CPZ the first known highly specific biomarker capable of accurately distinguishing true hepatocellular differentiation from hepatoid morphological mimicry. Based on this, this invention provides a novel differential diagnostic strategy—using a negative CPZ result to effectively exclude HCC, thereby avoiding misdiagnosis of gastric hepatocellular carcinoma, yolk sac tumors, etc., as metastatic. Summary of the Invention

[0006] The purpose of this invention is to solve the problem of how to efficiently and specifically distinguish hepatocellular carcinoma from hepatoid adenocarcinoma, yolk sac tumor, and other hepatoid differentiated or morphologically similar tumors, so as to overcome the technical problems of high false positive rate and insufficient specificity of existing markers in the above-mentioned tumors.

[0007] To address the aforementioned problems, the first aspect of this invention provides a biomarker for differentiating hepatocellular carcinoma from other hepatoid differentiation or germ cell-derived tumors, wherein the biomarker is CPZ protein.

[0008] A second aspect of the present invention provides the use of an antibody against CPZ protein in the preparation of a diagnostic reagent for differentiating hepatocellular carcinoma from other hepatoid differentiation or germ cell-derived tumors.

[0009] Preferably, the differential diagnosis is achieved by immunohistochemical detection of CPZ protein expression in biopsy or surgically removed tissue samples.

[0010] Preferably, the other hepatoid differentiation or germ cell-derived tumors include gastric hepatoid adenocarcinoma, rectal hepatoid adenocarcinoma, gallbladder hepatoid adenocarcinoma, yolk sac tumor, etc.

[0011] A third aspect of the present invention provides the use of a composition for detecting CPZ protein and HepPar-1 markers in the preparation of a diagnostic reagent for differentiating between hepatocellular carcinoma and hepatoid adenocarcinoma.

[0012] The fourth aspect of the present invention provides the use of a composition for detecting CPZ protein and SALL4 markers in the preparation of a diagnostic reagent for differentiating between hepatocellular carcinoma and yolk sac tumor.

[0013] A fifth aspect of the present invention provides a detection system that can be used to differentiate hepatocellular carcinoma from other hepatocellular differentiated or germ cell-derived tumors; the detection system includes a reagent for detecting CPZ protein.

[0014] The sixth aspect of this invention provides a detection method for differentiating between hepatocellular carcinoma and germ cell-derived tumors, the method comprising the following steps:

[0015] Step 1: Detect whether AFP and GPC3 are positive in hepatoid tumors;

[0016] Step 2: Detect the CPZ and SALL4 in the positive samples from Step 1;

[0017] Step 3: If the sample in Step 2 is positive for CPZ but negative for SALL4, then the sample is a hepatocellular carcinoma sample.

[0018] Step 4: If the sample in Step 2 is negative for CPZ or weakly positive for local foci, and positive for SALL4, then the sample is a germ cell-derived tumor, including yolk sac tumors.

[0019] A seventh aspect of the present invention provides a detection system that can be used to differentiate between hepatocellular carcinoma and germ cell-derived tumors; the detection system employs the detection method described above.

[0020] Compared with the prior art, the present invention has the following beneficial effects:

[0021] 1. The present invention provides CPZ antibody as an immunohistochemical antibody that can efficiently and specifically distinguish hepatocellular carcinoma from hepatoid adenocarcinoma, yolk sac tumor and other hepatoid differentiated or morphologically similar tumors, which can overcome the defects of existing markers in the above-mentioned tumors, such as high false positive rate and insufficient specificity.

[0022] 2. This invention can differentiate hepatocellular carcinoma from other hepatoid differentiated tumors or germ cell-derived tumors, providing support for developing more precise and effective individualized treatment strategies. Attached Figure Description

[0023] Figure 1 ROC curves for differentiating hepatocellular carcinoma from hepatocellular carcinoma using CPZ, HepPar-1, GPC3, and AFP.

[0024] Figure 2 ROC curves for differentiating hepatocellular carcinoma from yolk sac tumor using CPZ, HepPar-1, GPC3, AFP, and SALL4.

[0025] Figure 3 This is a comparison image of immunohistochemical staining between gastric hepatoid adenocarcinoma and yolk sac tumor.

[0026] Figure 4 This is a flowchart of the clinical pathological differential diagnosis based on CPZ. Detailed Implementation

[0027] To make the present invention more apparent and understandable, preferred embodiments are described in detail below with reference to the accompanying drawings:

[0028] This invention provides CPZ as an immunohistochemical marker that can efficiently and specifically differentiate hepatocellular carcinoma from hepatoid adenocarcinoma, yolk sac tumor, and other hepatoid differentiated or morphologically similar tumors, overcoming the shortcomings of existing markers in these tumors, such as high false positive rates and insufficient specificity. Experiments have shown that CPZ is almost completely absent in tumors such as hepatoid adenocarcinoma and yolk sac tumor, which are morphologically easily confused with hepatocellular carcinoma, indicating that CPZ is a more stringent indicator of hepatocellular lineage fidelity than traditional markers.

[0029] This invention provides the application of an antibody against CPZ protein in the preparation of a detection tool for differentiating hepatocellular carcinoma from other hepatoid or germ cell-derived tumors via immunohistochemical detection. This application is achieved by detecting the expression of CPZ protein in biopsy or surgically resected tissue samples. If the sample shows positive expression of CPZ protein, it suggests that the sample is likely to be hepatocellular carcinoma; if the sample shows negative or very weak positive expression of CPZ protein, while traditional markers (such as GPC3 and AFP) are positive, it suggests that the sample may be a hepatoid-derived tumor rather than true hepatocellular carcinoma.

[0030] In one specific application, the other hepatoid differentiation or germ cell-derived tumors are selected from at least one of gastric hepatoid adenocarcinoma, rectal hepatoid adenocarcinoma, gallbladder hepatoid adenocarcinoma, and yolk sac tumor.

[0031] Furthermore, when the other hepatocellular differentiated or germ cell-derived tumors are yolk sac tumors, CPZ can be combined with SALL4 for dual differential diagnosis. The combination of a negative CPZ and a positive SALL4 can precisely shift the diagnostic focus from hepatocellular carcinoma metastasis to germ cell-derived tumors such as yolk sac tumors.

[0032] Example 1: Application of CPZ antibody in the differential diagnosis of hepatocellular carcinoma and hepatocellular carcinoma

[0033] In this invention, the CPZ antibody used is a self-developed CPZ monoclonal antibody (for IHC, immunohistochemistry) 1E3 antibody; other antibodies are from commercially available products.

[0034] Preservation Information

[0035] Hybridoma cell line 1E3, which secretes the monoclonal antibody CPZ, was deposited on July 21, 2026, at the China Center for Type Culture Collection (CCTCC), located at Wuhan University, No. 299 Bayi Road, Wuchang District, Wuhan, Hubei Province, 430072, China. The accession number for hybridoma cell line 1E3 is CCTCC NO: C2026152. All the above deposits were made in accordance with the Patent Cooperation Treaty, and the cell line is in viable condition.

[0036] Immunohistochemical staining was performed on 55 hepatocellular carcinoma tissue samples using a CPZ antibody from clone 1E3 (a CPZ monoclonal antibody constructed by the inventors' team and deposited at the China Center for Type Culture Collection (CCTCC)). The results showed that 36 of the 55 hepatocellular carcinoma tissue samples did not express CPZ, while 19 showed varying degrees of positive expression, ranging from 1% to 30%, with most showing weak positivity, resulting in a positive expression rate of 34.5%. In the same batch of hepatocellular carcinoma tissue, IHC staining for HepPar-1, AFP, GPC3, and SALL4 was also performed. The results showed that 50 samples did not express HepPar-1, while 5 showed varying degrees of positive expression, ranging from 1% to 2%, with most showing weak positivity, resulting in a positive expression rate of 9.1%. 8 samples did not express GPC3, while 47 showed varying degrees of positive expression, ranging from 1% to 100%, with most showing strong positivity, resulting in a positive expression rate of 85.5%. Sixteen cases did not express AFP, while 39 cases showed varying degrees of positive expression, ranging from 1% to 100%, with most showing strong positivity and a positive expression rate of 70.9%. Three cases did not express SALL4, while 50 cases showed varying degrees of positive expression, ranging from 1% to 100%, with a positive expression rate of 94.30%. This indicates that GPC3 and AFP cannot distinguish between hepatocellular carcinoma and hepatoid adenocarcinoma, while a negative or focally weakly positive CPZ expression pattern can effectively exclude hepatocellular carcinoma.

[0037] Further ROC curve analysis was performed to evaluate the diagnostic efficacy of CPZ, HepPar-1, GPC3, and AFP in differentiating hepatocellular carcinoma (100 cases) from hepatoid adenocarcinoma (55 cases). The results showed that CPZ had an AUC of 0.981 (95% CI: 0.944–0.996), with a sensitivity of 91% and specificity of 100% at an optimal cutoff value >0.4. HepPar-1 had an AUC of 0.951 (95% CI: 0.904–0.979), with a sensitivity of 91% and specificity of 100% at an optimal cutoff value >0.02. GPC3 had an AUC of 0.758, and AFP had an AUC of 0.732; the latter two had limited diagnostic value in differentiating between the two.

[0038] A binary logistic regression model constructed by combining CPZ and HepPar-1 achieved an AUC of 1.000 (95% CI: 0.976–1.000, P < 0.001), with both sensitivity and specificity at 100% and a Youden index of 1.000, completely distinguishing hepatocellular carcinoma from hepatoid adenocarcinoma. This result stems from the perfect complementarity of the two biomarkers in their biological functions—CPZ, as a faithful marker of hepatocellular lineage, has high sensitivity, while HepPar-1, as a functional marker of hepatocellular carcinoma, has high specificity. In clinical applications, combined detection of CPZ and HepPar-1 is recommended for the differential diagnosis of hepatocellular carcinoma and hepatoid adenocarcinoma: diffuse strong CPZ positivity strongly suggests hepatocellular origin, and if HepPar-1 is also positive, hepatocellular carcinoma can be definitively diagnosed (positive predictive value 97.80%, specificity 96.36%). A negative CPZ test or only a focal weak positive result, while GPC3 and / or AFP are positive, should raise strong suspicion of hepatomorphic differentiated tumors such as hepatomorphic adenocarcinoma, rather than hepatocellular carcinoma (the negative predictive value of CPZ in excluding HCC is 94.74%). This combined detection strategy utilizes the lineage specificity (high sensitivity) of CPZ and the functional confirmatory value (high specificity) of HepPar-1, effectively reducing the risk of misdiagnosing hepatomorphic adenocarcinoma as hepatocellular carcinoma.

[0039]

[0040]

[0041] Example 2: Application of CPZ antibody in the differential diagnosis of yolk sac tumor and hepatocellular carcinoma

[0042] Immunohistochemical staining for CPZ was performed on 39 yolk sac tumor tissue samples. The results showed that none of the 39 yolk sac tumors expressed CPZ, with a positive rate of 0%. In the same batch of yolk sac tumor tissues, IHC staining for HepPar-1, AFP, GPC3, and SALL4 was also performed. The results showed that 21 cases did not express HepPar-1, while 18 cases showed varying degrees of positive expression, ranging from 1% to 5%, with positive intensities mostly +-++, resulting in a positive expression rate of 53.8%. Three cases did not express GPC3, while 36 cases showed varying degrees of positive expression, ranging from 1% to 90%, with positive intensities mostly +-++, resulting in a positive expression rate of 92.3%. Five cases did not express AFP, while 34 cases showed varying degrees of positive expression, ranging from 2% to 90%, with positive intensities mostly weak +-++, resulting in a positive expression rate of 87.2%. Three cases did not express SALL4, while 36 cases showed varying degrees of positive expression, ranging from 2% to 100%, with positive intensities mostly ranging from + to ++, and a positive expression rate of 92.3%. These results indicate that GPC3 and AFP are widely and highly expressed in yolk sac tumors, rendering them unsuitable for differentiation from hepatocellular carcinoma. The complete negative expression of CPZ in yolk sac tumors provides a decisive basis for ruling out hepatocellular carcinoma.

[0043] ROC curve analysis showed that CPZ had an AUC of 0.99 (95% CI: 0.956-0.999) to differentiate hepatocellular carcinoma from yolk sac tumor, with a sensitivity of 98% and a specificity of 100%. This means that a positive CPZ result strongly supports the diagnosis of hepatocellular carcinoma, while a negative CPZ result strongly suggests a non-hepatocellular origin and effectively excludes hepatocellular carcinoma.

[0044] Given that the SALL4 positivity rate in yolk sac tumors is 92.3%, while the CPZ positivity rate in hepatocellular carcinoma is as high as 98%, a dual diagnostic logic can be constructed by using a combined interpretation rule of CPZ negativity and SALL4 positivity: CPZ negativity first excludes hepatocellular carcinoma, while SALL4 positivity further identifies tumors of germ cell origin. This combined strategy overcomes the limitation of the limited specificity (73.33%) of SALL4 detection alone, significantly improving the differential diagnostic value for yolk sac tumors while maintaining high sensitivity. This helps avoid misdiagnosing yolk sac tumors as hepatocellular carcinoma, or missing the diagnosis of SALL4-positive hepatocellular carcinoma.

[0045]

[0046]

[0047] Note: Data on CPZ, HepPar-1, GPC3, and AFP in hepatocellular carcinoma are from Deng M, et al. Am J SurgPathol, 2025. Data on all markers in hepatocellular adenocarcinoma and yolk sac tumor are experimental results from this invention.

[0048] In the attached image: Figure 1 ROC curves for differentiating hepatocellular carcinoma from hepatocellular carcinoma using CPZ, HepPar-1, GPC3, and AFP.

[0049] Figure 2 ROC curves for differentiating hepatocellular carcinoma from yolk sac tumor using CPZ, HepPar-1, GPC3, AFP, and SALL4.

[0050] Figure 3 These are comparison images of immunohistochemical staining in hepatomorphic adenocarcinoma and yolk sac tumor. Figure A1 shows HE staining of hepatomorphic adenocarcinoma. Figure A2 shows that hepatomorphic adenocarcinoma does not express CPZ. Figure A3 shows that GPC3 is positively expressed in hepatomorphic adenocarcinoma. Figure A4 shows that AFP is diffusely strongly positively expressed in hepatomorphic adenocarcinoma. Figure B1 shows HE staining of yolk sac tumor. Figure B2 shows that yolk sac tumor does not express CPZ. Figure B3 shows that SALL4 is diffusely strongly positively expressed in yolk sac tumor. Figure B4 shows that HepPar-1 is partially positively expressed in yolk sac tumor. Figure B5 shows that GPC3 is diffusely strongly positively expressed in yolk sac tumor. Figure B6 shows that AFP is diffusely strongly positively expressed in yolk sac tumor.

[0051] Figure 4 This is a flowchart of the clinical pathological differential diagnosis based on CPZ.

[0052] The above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention in any form or substance. It should be noted that those skilled in the art can make various improvements and additions without departing from the present invention, and these improvements and additions should also be considered within the scope of protection of the present invention. Any modifications, alterations, and equivalent changes made by those skilled in the art based on the above-disclosed technical content without departing from the spirit and scope of the present invention are equivalent embodiments of the present invention. Furthermore, any modifications, alterations, and evolutions made to the above embodiments based on the essential technology of the present invention still fall within the scope of the technical solution of the present invention.

Claims

1. A biomarker for differentiating hepatocellular carcinoma from other hepatocellular differentiated or germ cell-derived tumors, characterized in that, The biomarker is CPZ protein.

2. The application of an antibody against CPZ protein in the preparation of a diagnostic reagent for differentiating hepatocellular carcinoma from other hepatocellular differentiated or germ cell-derived tumors.

3. The application according to claim 2, characterized in that, The differential diagnosis is achieved by immunohistochemical detection of CPZ protein expression in biopsy or surgically removed tissue samples.

4. The application according to claim 2, characterized in that, Other hepatoid differentiation or germ cell-derived tumors include gastric hepatoid adenocarcinoma, rectal hepatoid adenocarcinoma, gallbladder hepatoid adenocarcinoma, and yolk sac tumor.

5. The use of a composition for detecting CPZ protein and HepPar-1 markers in the preparation of a diagnostic reagent for differentiating between hepatocellular carcinoma and hepatoid adenocarcinoma.

6. The use of a composition for detecting CPZ protein and SALL4 markers in the preparation of a diagnostic reagent for differentiating between hepatocellular carcinoma and yolk sac tumor.

7. A detection system, characterized in that, The detection system can be used to differentiate hepatocellular carcinoma from other hepatoid differentiated or germ cell-derived tumors; the detection system includes reagents for detecting CPZ protein.

8. A detection method for differentiating hepatocellular carcinoma from germ cell-derived tumors, characterized in that, The method includes the following steps: Step 1: Detect whether AFP and GPC3 are positive in hepatoid tumors; Step 2: Detect the CPZ and SALL4 in the positive samples from Step 1; Step 3: If the sample in Step 2 is positive for CPZ but negative for SALL4, then the sample is a hepatocellular carcinoma sample. Step 4: If the sample in Step 2 is negative for CPZ or weakly positive for local foci, and positive for SALL4, then the sample is a germ cell-derived tumor, including yolk sac tumors.

9. A detection system, characterized in that, The detection system can be used to differentiate between hepatocellular carcinoma and germ cell-derived tumors; the detection system employs the detection method described in claim 8.

Citation Information

Patent Citations

  • CPZ immunohistochemical antibody and application

    CN119176881A